Finally, $NANOX officially announced its offline participation in #RSNA. It has been a long time since I decided to invest in $NNOX. The reason why I chose it as a retirement item is because the founder suddenly died of liver cancer amid suspicions of scams due to numerous bad reviews, malicious criticism, and responsibility that was not shown in time,,, It is also because I visited Yongin Fab twice in 2022 and 2023 and confirmed the actual operation of the cold cathode, but it is also because I recognized the reality that many people who were fighting for their lives during the pandemic and unfortunately passed away, and many people who are still suffering from aftereffects are being bombarded with excessive radiation CT, but there is no proper solution, and they are continuously being attacked by radiation even at a level where they cannot tell whether it is a disease or a medicine, and are undergoing in-depth diagnosis. #Nanox's next version Arc-X is without a doubt the first step to realize the grand ambition, but the management should report a thousand times more honestly than the founder, and should not repeat the incident of replacing the nonsensical staff who opportunistically talk nonsense and deceiving investors with unmaintainable timelines. If cost-effective, affordable low-dose lung diagnosis is made, a realistic foundation for creating a public health market will be newly formed, and all the health institutions in the world will have to think together and implement a policy to encourage early diagnosis and progress monitoring solutions for chronic diseases nationwide. $Nanox's only competitive edge is the real end-user, medical finance and insurance (Reimbursement) reduction, which is a breakthrough, and there are great expectations. With the confidence that it will become a national and global low-power safety solution for excessive medical expenses, we hope that this first RSNA participation will change the image to a new approach of low-dose, low-power, low-price, but with the highest quality service. picture source: Effectiveness of COVID-19 Vaccines Over Time Against Clinical and Radiologic Outcomes Related to Severe SARS-CoV-2 Infection

$NNOX youtube.com/watch?v=4TRwGHPj…

$nnox $ai Big news from #ECR2026! We're honored and excited to share that Nanox has been named #ECR 2026 Newcomer of the Year! Thank you to the European Congress of Radiology and to everyone who continues to support innovation in healthcare.

$NNOX #InvestorRelations #tomosynthesis $ai #mbx RSNA Innovation theater with Dr. Orit Wimpfheimer 2025 youtube.com/watch?v=DJMAO9MK…

$NNOX 2026 Full Year Guidance: $35M Based on the "Pre-Orders". #Arc-X mass production: hundreds of units are in progresses #IntuitiveSurgical was once a penny stock too. Now? The undisputed king of robotic surgery. What they share: Multi-year manufacturing partnership with #FABRINET Precision robotics engineering capability Penny stock → Market dominator The #ISRG story. The $NNOX story in progress. History rhymes.

$NNOX $NANOX This is the world's most advanced X-ray source revolution, and the evidence silences its critics. It's all true, and I'm basing it on facts. This is the world's most advanced X-ray source revolution, and the evidence that silences its critics. It's all true, and it's based on facts. And that's not even all. It's just a part of it.

$NNOX $NANOX TAP2D superiority

$NNOX $NANOX

Although $Nanox has yet to officially announce its Mammo market entry, allowing its many critics to see the truth, having studied $NNOX for over five years, I can confidently present the table below with sufficient evidence and facts. Nanox's mammography/DBT market entry is strategically feasible. Cold Cathode Multi-Source Technology provides an exclusive competitive advantage that major OEMs cannot replicate. Direct MSaaS OEM Partnership Hybrid Strategy. This clearly demonstrates that management is already preparing for explosive growth in addition to exponential growth in Q3 2025.

Those who spent years claiming " $NNOX MEMS doesn't work" are now watching #Varex integrate it into their flagship platform while their preferred CNT technology faces FDA scrutiny. The silence from the critic camp speaks volumes.

youtu.be/EIyAmEzgU4I?feature… After completing field testing and clinical validation of product lineup (durability - performance, degradation defense mechanisms) $NANOX appear to be beginning full-scale marketing and promotion. $NNOX #Arc-X Tube (and Chip) OEM - All Industries AI Solutions Three years late to launch, but three years early It will dominate the global market.

$Nanox.ARC - X $NNOX 2025 RSNA

What I learned during the $NNOX feasibility study, Despite the complete lack of recognition for 2D CXR as a equip for early "lung cancer screening", approximately "33 million" cases are being performed annually, wasting valuable funds. When $NANOX receives #TAP2D approval and becomes a standalone device, the #Arc-X will creates a significant contribution, while also reducing the cost of duplicate scans. Even in terms of CapEx, the 3D tomosynthesis Arc-X, including end-to-end services, was found to be cheaper than the 2D CXR equipment options.

$Nanox.ARC - X $NNOX Cold Cathode with breakthrough imaging technology.

linkedin.com/posts/tv-radiol… $NANOX Arc-X $NNOX

linkedin.com/posts/rsna-nano… $NANOX Arc-X $NNOX

linkedin.com/posts/radiology… Wonder I am. $NANOX Arc-X and multi beam array #Varex`s enveloped glass tube $NNOX Mems Chip

linkedin.com/posts/radiology… 2025 RSNA Day -3 $NANOX Arc-X reviewed by #RadiologyBusiness $NNOX